methyl 3-(5-bromopentyl)-5-(2-methoxy-2-oxoethyl)-4H-1,2-oxazole-5-carboxylate | 213542-05-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 3-(5-bromopentyl)-5-(2-methoxy-2-oxoethyl)-4H-1,2-oxazole-5-carboxylate
• CAS: 213542-05-3
• 化学式: C₁₃H₂₀BrNO₅
• 分子量: 350.21
• InChiKey: NOQSBVFXGDQPRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  74.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 3-(5-bromopentyl)-5-(2-methoxy-2-oxoethyl)-4H-1,2-oxazole-5-carboxylate 在 Ra-Ni 氢氧化钾 、 氢气 、 硼酸 作用下， 以 甲醇 为溶剂， 反应 4.75h， 生成
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. 2. Synthesis and Evaluation of (3R*,5S*)-ω-Substituted-3-carboxy-3,5-dihydroxyalkanoic Acids and Their γ-Lactone Prodrugs as Inhibitors of the Enzyme in Vitro and in Vivo

  摘要：

  series of (3R*,5S*)-omega-substituted-3-carboxy-3,5-dihydroxyalkanoic acids have been synthesized and evaluated as inhibitors of the recombinant human form of ATP-citrate lyase. The best of these have K-i's in the 200-1000 nM range. As the corresponding thermodynamically favored gamma-lactone prodrugs, a number of compounds are able to inhibit cholesterol and fatty acid synthesis in HepG2 cells and reduce plasma triglyceride levels in vivo. The best of these, compound 77, is able to induce clear hypocholesterolemic and hypotriglyceridaemic responses when administered orally to rat and dog. These results provide evidence to support the hypothesis that compounds which inhibit ATP-citrate lyase have the potential to be a novel class of hypolipidemic agent, which possess combined hypocholesterolemic and hypotriglyceridemic activities.

  DOI：

  10.1021/jm980091z
• 作为产物：
  描述：

  衣康酸二甲酯 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.5h， 生成 methyl 3-(5-bromopentyl)-5-(2-methoxy-2-oxoethyl)-4H-1,2-oxazole-5-carboxylate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. 2. Synthesis and Evaluation of (3R*,5S*)-ω-Substituted-3-carboxy-3,5-dihydroxyalkanoic Acids and Their γ-Lactone Prodrugs as Inhibitors of the Enzyme in Vitro and in Vivo

  摘要：

  series of (3R*,5S*)-omega-substituted-3-carboxy-3,5-dihydroxyalkanoic acids have been synthesized and evaluated as inhibitors of the recombinant human form of ATP-citrate lyase. The best of these have K-i's in the 200-1000 nM range. As the corresponding thermodynamically favored gamma-lactone prodrugs, a number of compounds are able to inhibit cholesterol and fatty acid synthesis in HepG2 cells and reduce plasma triglyceride levels in vivo. The best of these, compound 77, is able to induce clear hypocholesterolemic and hypotriglyceridaemic responses when administered orally to rat and dog. These results provide evidence to support the hypothesis that compounds which inhibit ATP-citrate lyase have the potential to be a novel class of hypolipidemic agent, which possess combined hypocholesterolemic and hypotriglyceridemic activities.

  DOI：

  10.1021/jm980091z

文献信息

• ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. 2. Synthesis and Evaluation of (3<i>R</i>*,5<i>S</i>*)-ω-Substituted-3-carboxy-3,5-dihydroxyalkanoic Acids and Their γ-Lactone Prodrugs as Inhibitors of the Enzyme in Vitro and in Vivo
  作者：Andrew D. Gribble、Robert J. Ife、Antony Shaw、David McNair、Christine E. Novelli、Susan Bakewell、Virendra P. Shah、Roland E. Dolle、Pieter H. Groot、Nigel Pearce、John Yates、David Tew、Helen Boyd、Stephen Ashman、Drake S. Eggleston、R. Curtis Haltiwanger、George Okafo

  DOI：10.1021/jm980091z

  日期：1998.9.1

  series of (3R*,5S*)-omega-substituted-3-carboxy-3,5-dihydroxyalkanoic acids have been synthesized and evaluated as inhibitors of the recombinant human form of ATP-citrate lyase. The best of these have K-i's in the 200-1000 nM range. As the corresponding thermodynamically favored gamma-lactone prodrugs, a number of compounds are able to inhibit cholesterol and fatty acid synthesis in HepG2 cells and reduce plasma triglyceride levels in vivo. The best of these, compound 77, is able to induce clear hypocholesterolemic and hypotriglyceridaemic responses when administered orally to rat and dog. These results provide evidence to support the hypothesis that compounds which inhibit ATP-citrate lyase have the potential to be a novel class of hypolipidemic agent, which possess combined hypocholesterolemic and hypotriglyceridemic activities.